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Asthma is a common, potentially serious, even life-threat-
ening,  chronic  medical  condition  seen  amongst  nearly  all 
groups of patients, regardless of ethnicity and socioeconomic 
circumstances. This article addresses the group of pregnant 
women with  symptomatic  asthma  as well  as  those whose 
asthma is asymptomatic as a result of good control. The clas-
sification  of  these  patients  and  appropriate  management 
strategies are discussed.
Overall,  the prevalence and morbidity of asthma are  in-
creasing;  although mortality  rates  have  decreased.1   Asth-
ma  complicates  3.7%  to  8.4%  of  all  pregnancies—between 








Treatment  varies,  based  on  the  severity  classification  of 
each individual patient’s asthma and includes avoidance of 





Asthma  is  characterized  by  paroxysmal  or  persistent 
symptoms of broncho-constriction including breathlessness, 




in pregnancy  is no different  from that  in  the non-pregnant 
patient.
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Possible  mechanisms  include  maternal  hormone  changes 



































nancies  should  be  reviewed.  Schatz  and  colleagues  noted 
that when subjects were assessed in successive pregnancies, 
60%  of  them  followed  the  same  course  with  their  asthma 






Table  1  presents  the  National  Institutes  of  Health  clas-




















op worsening  of  control  during  pregnancy,  therefore  close 
























and  less  than  50%  of  the  patient’s  personal  best.  Patients 
should be advised that 80% or more of PEFR is considered 
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	Symptoms more than twice 
per week, but not daily
	Nocturnal symptoms more 










	Symptoms twice per week 
or less
	Nocturnal symptoms twice 
per month or less
	FEV
1
 80% of predicted or 
more






	Nocturnal symptoms more 
than once per week
	FEV
1 
more than 60% to 
less than 50% predicted.  
	Regular medications 
























salmeterol AND oral 
corticosteroid if needed 
	Albuterol as needed
For acute symptoms: Albuterol 2-6 puffs as needed for FEV1 less than 80%, exposure to allergens or exercise should supplement all treatment 
plans.  May repeat in 20 minutes.  If no response then patient should seek medical attention.  May need  a short burst of  methylprednisone 40-
60mg daily in a single or divided dose for 3-10 days, no taper needed
Adapted from National Heart, Lung, and Blood Institute, National Ashtma Edication and Prevention Program.  Expert panel report: guidelines for the 
diagnosis and management of asthma.  NIH Publication No. 05-5236.  Bethesda (MD): NHLBI.  Available at http:// www.nhlbi.nih.gov/health/prof/lung/
asthma/astpreg/astpreg_full.pdf
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however,  there  may  be  physiologic  changes  in  pregnancy 





bronchodilator  therapy.  At  least  twice  during  pregnancy, 
treatment should be reviewed and stepped up if symptoms 
are persistent; or,  if  symptoms are well  controlled,  therapy 
can be maintained or even decreased.9  
Inhaled Corticosteroids
Inhaled  corticosteroids  (ICS)  are  preferred  for  the man-
agement of all levels of persistent asthma in pregnancy.9 Cor-








The  most  well  studied  inhaled  corticosteroid  is 
budesonide.13  Because  there  are  more  data  regarding  this 
medication  than  other  corticosteroids,  budesonide  is  con-















available  (eg,  Proventil  to  Proventil HFA,  Schering-Plough 
Corporation). It is important to inquire at each prenatal visit 
how often the patient has needed to use her β2 agonist  in-
haler.  9, 15  If a patient requires more  than 2  inhalation treat-
ments with a β agonist in a week, this indicates the need for 
an additional preventative maintenance agent such as ICS.
Leukotriene Moderators, Cromolyn and  
Theophylline
Leukotrience  moderators,  cromolyn  and  theophylline 
are  alternative  treatments  for  mild  persistent  asthma  and 








if  PEFR  is  within  the 
50%  to  80%  range  she 
should  arrange  an  ap-







Explanation  of  the  importance  of  optimal  asthma  control 
and  the  risks  of  poor  control  for  the  patient  and  the  fetus 
should be discussed early in pregnancy. Patients should be 
taught how to do peak flow measurements, how to  record 
the  results,  and what values  should be of  concern,  as well 
as who to contact in emergent situations. Patients should be 
observed using their inhalers and peak flow meters and cor-
rect use  reinforced. Frank discussion about  the  importance 




Up  to  80%  of  patients  with  asthma  have  positive  skin 
tests  to  allergens,  the most  common  being  animal  dander, 
dust mites,  cockroach  antigens,  pollens,  and molds.  There 
are  non-immune  triggers  as  well,  including  strong  odors, 
tobacco  smoke,  air  pollutants,  and  drugs  such  as  aspirin 




of  exacerbations  during  and  after  pregnancy.  All  patients 
should be  strongly  encouraged  to  stop  smoking,  but  espe-
cially  those with asthma because  they are at  increased risk 
for worsening chronic and acute asthma sequelae.
Pharmacotherapy
Medical  therapy  includes a  stepwise approach  in an at-




toms,  exacerbations,  or  limitations  on  activities.  The  final 
goal is to minimize the adverse effects of treatment. It is safer 
for pregnant women with asthma to be treated with asthma 
medications  than  to  have  exacerbations  or  asthma  symp-
toms.9    It  is assumed  that asthma medications are as effec-
tive in the pregnant patient as in the non-pregnant woman; 
Figure 1: Peak Flow Meter 11
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Management of an Acute Asthma Exacerbation 
in Pregnancy
An asthma exacerbation in a pregnant woman places both 





pregnancy,  and many  of  these women  require  hospitaliza-
tion.






tion  with  inhaled  β2  agonists  and  corticosteroids  (oral  or 






Possible  differential  diagnoses  of  a  severe  exacerbation 
unresponsive to initial treatment should include pulmonary 
edema,  pulmonary  embolism,  cardiomyopathy,  and  amni-
otic fluid embolism. 
Refractory  status  asthmaticus  is  defined  as  a  severe  ex-
acerbation  of  asthma  that  is  unresponsive  to  bronchodila-
tors and corticosteroids and that requires intensive care unit 
admission and typically mechanical ventilation.  In patients 










who  underwent  cesarean  delivery  and  improved  dramati-
cally after the procedure.16-18











Management of Asthma During Labor and  
Delivery
Asthma medications  should  not  be  discontinued  or  de-
layed  during  labor  and  delivery. Although  asthma  during 
labor  is  typically  quiescent,  consideration  should  be  given 
to  obtaining  a  peak  flow measurement  on  admission  and 
then  every  12  hours  or  as  needed  to  monitor  for  asthma 
exacerbation.  Monitoring  is  likely  only  necessary  in  those 
women who  have  a  history  of  exacerbations  during  preg-
nancy. Neuraxial anesthesia decreases oxygen requirements 
and minute ventilation and  thus can be helpful  for control 








bor,  and during delivery  can have  an  influence on  asthma 
symptoms, especially in the most severe or medication sen-
sitive  asthmatic  patients.  Prostaglandins  E2  or  E1  can  be 




ergonovine,  and  rarely  methylergonovine  can  cause  bron-
chospasm, especially in the aspirin-sensitive patient.21-22 For 
these patients,  choosing  a medication  such  as misoprostol, 
which is an E1, may be more appropriate.
Magnesium  sulfate  is  a  bronchodilator,  and  should  not 
have a deleterious  effect on asthma, but  indomethacin  can 
induce  bronchospasm  in  an  asthmatic patient with  known 
aspirin  sensitivity.  No  formal  studies  on  calcium  channel 
blockers  in  the  asthmatic  gravid  patient  have  been  pub-
lished,  but  bronchospasm  has  not  been  observed with  the 
wide clinical use of these medications for tocolysis.
Breastfeeding
Asthma medications  are  excreted  in  small  and  varying 
amounts into breast milk. The NAEPP found that there was 
no  contraindication  for  the  use  of  prednisone,  theophyl-
line, cromolyn, antihistamines, ICS, or inhaled b agonist for 










ening  of  their  asthma,  including  those  women  with  mild 
asthma. There are proven negative effects from exacerbations 
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and poor control on pregnancy outcome, whereas there are 
clear  benefits  of  good  control.  Patient  education  about  the 
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